Advanced Viral Research Corp., of Yonkers, N.Y., was awarded U.S. Patent No. 6,355,226 titled “Topical Treatment for Skin Disease and Eye Afflictions,” covering the use of Product R, the nontoxic peptide-nucleic acid immunomodulator developed by the company.

Alexion Pharmaceuticals Inc., of Cheshire, Conn., was issued U.S. Patent No. 6,355,245 titled “C-Specific Antibodies for the Treatment of Inflammatory Diseases.” The claims relate to the company’s C5 complement inhibitor program and cover the composition and use of its lead drug candidates, eculizumab and pexelizumab, as well as other antibodies that bind to C5 and inhibit its inflammatory activity.

Battelle Pulmonary Therapeutics, of Columbus, Ohio, was issued U.S. Patent No. 6,348,209 titled “Formulation and Method for Treating Neoplasms by Inhalation,” which covers a method for treating lung cancer by inhalation.

Digital Gene Technologies Inc., of La Jolla, Calif., was issued U.S. Patent No. 6,334,099 covering methods for normalizing gene expression data and empowering TOGA’s capacity for cross-experiment comparisons of gene expression.

Diversa Corp., of San Diego, was issued U.S. Patent No. 6,352,842 directed to its exo-mediated fragment hybridization evolution technology used to produce genes and proteins. It was also awarded U.S. Patent No. 6,358,709 directed to its GeneReassembly evolution technology, which further expands the patent estate. GeneReassembly creates populations of nucleic acid fragments of varying lengths and then reassembles them to generate new genetic variants. Diversa also was issued U.S. Patent No. 6,361,974, its second patent this year related to the exo-mediated fragment hybridization evolution technology. The patent is directed to a random, recombination-based method for producing hybrid polynucleotides that encode useful bioactivities by using an exonuclease-mediated reassembly process.

GPC Biotech AG, of Martinsried, Germany, was issued U.S. Patent No. 6,342,356 describing genetic approaches to elucidate molecular differences between normal and diseased cells that can be exploited for drug discovery. The methods and reagents covered in the patent allow GPC Biotech to identify validated drug targets in diseased cells.

Immunomedics Inc., of Morris Plains, N.J., was issued U.S. Patent No. 6,361,774 covering a new method for targeting drugs to selective diseases, including cancers. The invention uses an enzyme attached to an antibody that converts an inactive drug to a more cell-killing form.

Large Scale Biology Corp., of Vacaville, Calif., was issued U.S. Patent No. 6,344,597 covering a new plant species designated Nicotiana excelsiana. The patent relates to plant species that have enhanced properties for protein production using LSBC’s Geneware technology.

Lipocine Inc., of Salt Lake City, was issued four patents by the U.S. Patent and Trademark Office covering its core technology programs. U.S. Patent No. 6,267,985 relates to compositions and methods for the improved delivery of hydrophobic and hydrophilic therapeutic agents; U.S. Patent No. 6,309,663 related to compositions, systems and methods for enhanced absorption of hydrophilic agents; U.S. Patent No. 6,294,192 relates to compositions and methods for the improved delivery of hydrophobic agents; and U.S. Patent No. 6,248,363 relates to solid compositions for the improved delivery of active agents.

Parker Hughes Institute, of Roseville, Minn., was granted U.S. Patent No. 6,350,736 for Stampidine, a new anti-AIDS drug developed at the institute. Parker Hughes completed all preclinical research and development related to Stampidine and is preparing to seek FDA approval to begin clinical trials.

Peplin Biotech Ltd., of Brisbane, Australia, was issued its first U.S. patent covering the use of its molecules for the topical treatment of skin cancers including melanoma, Merkel cell carcinoma, squamous cell carcinoma, basal cell carcinoma and solar keratosis.

Phylonix Pharmaceuticals Inc., of Cambridge, Mass., was issued U.S. Patent No. 6,299,858 titled “Methods of Screening Agents for Activity Using Teleosts.” The patent covers methods of screening drugs for effects on cell death activity in zebrafish.

Signature BioScience Inc., of Hayward, Calif., was issued U.S. Patent No. 6,338,968 covering aspects of its core technology, multipole coupling spectroscopy, which is a key component of its drug discovery platform, WaveScreen. The patent covers a method for detecting binding of any ligand to any antiligand without use of a label by analyzing the dielectric properties of the bound molecular complex. Signature BioScience also was issued U.S. Patent No. 6,338,968 related to its MCS technology and covering technology for detecting nucleic acid hybridization, specifically detection of hybridization without requiring the separation of unbound from bound nucleic acids, thereby speeding up the detection of hybridization.

Symyx Technologies Inc., of Santa Clara, Calif., was issued U.S. Patent No. 6,346,290 covering methods widely used for high-throughput parallel synthesis of polymers. With this patent, Symyx expands its position in polymer and catalytic research.

Syrrx Inc., of San Diego, said it and the University of California’s Lawrence Berkeley National Lab were issued U.S. Patent No. 6,296,673 containing claims directed toward the use of very small volumes of liquid to enable the formation of crystals. The patent is licensed exclusively to Syrrx for commercial use with third parties.